Viventia Bio (Canada)
Viventia is using fusion protein technology to develop a pipeline of fully biologic molecules combining both the precision targeting of antibody fragments and the tumor cell killing power of protein cytotoxins. Viventia refers to these fully biologic entities as targeted protein therapeutics (TPTs) and is developing them for diseases in oncology. Viventia is advancing a broad pipeline of Targeted Protein Therapeutics (TPTs), which are fully biologic fusion constructs containing antibody fragment
Basic Information
- Category: business
- Website: http://www.viventia.com/
Documented Facts
- Inception (Wikidata): 1995 (Source 2: Wikidata Q30295526, revision 2474209022)
- Country (Wikidata; date unspecified): Canada (Source 2: Wikidata Q30295526, revision 2474209022; Source 3: Wikidata label: Q16, revision 2555105353)
- Official website (Wikidata; date unspecified): http://www.viventia.com/ (Source 2: Wikidata Q30295526, revision 2474209022)
Evidence and Sources
- Viventia Bio (Canada) — Official Website (official)
- Wikidata Q30295526, revision 2474209022 (knowledge-base)
- Wikidata label: Q16, revision 2555105353 (knowledge-base)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Viventia Bio (Canada).
- Canonical profile: https://brandsource.ai/brands/viventia-bio-canada
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/viventia-bio-canada/json-ld
- Citation profile API: https://brandsource.ai/api/brands/viventia-bio-canada/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (91/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Viventia is using fusion protein technology to develop a pipeline of fully biologic molecules combining both the precision targeting of antibody fragments and the tumor cell killing power of protein cytotoxins. Viventia refers to these fully biologic entities as targeted protein therapeutics (TPTs) and is developing them for diseases in oncology. Viventia is advancing a broad pipeline of Targeted Protein Therapeutics (TPTs), which are fully biologic fusion constructs containing antibody fragment
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 2 supporting sources linked.
- 3 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.